Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTAW) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to $54.9 million.

  • Strata Critical Medical's Operating Expenses rose 2726.51% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $348.1 million, marking a year-over-year increase of 3002.6%. This contributed to the annual value of $282.6 million for FY2024, which is 364.07% down from last year.
  • Strata Critical Medical's Operating Expenses amounted to $54.9 million in Q3 2025, which was up 2726.51% from $75.8 million recorded in Q2 2025.
  • Over the past 5 years, Strata Critical Medical's Operating Expenses peaked at $155.6 million during Q4 2024, and registered a low of $13.5 million during Q1 2021.
  • Over the past 5 years, Strata Critical Medical's median Operating Expenses value was $57.8 million (recorded in 2022), while the average stood at $59.2 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 1859772.48% in 2021, then plummeted by 4529.85% in 2024.
  • Strata Critical Medical's Operating Expenses (Quarter) stood at $35.2 million in 2021, then skyrocketed by 64.46% to $57.8 million in 2022, then surged by 43.76% to $83.1 million in 2023, then soared by 87.18% to $155.6 million in 2024, then plummeted by 64.7% to $54.9 million in 2025.
  • Its Operating Expenses stands at $54.9 million for Q3 2025, versus $75.8 million for Q2 2025 and $61.9 million for Q1 2025.